Sofosbuvir

Form: Film-coated Tablets

Strength: 400 mg

Reference Brands: Sovaldi® (EU & US)

Category: Hepatitis

Sofosbuvir Tablets are direct-acting antiviral agents (DAAs) used in combination therapy for the treatment of chronic Hepatitis C (HCV) across multiple genotypes. A nucleotide analog NS5B polymerase inhibitor, Sofosbuvir is available in 400 mg strength and forms the backbone of several pan-genotypic HCV regimens. Manufactured under EU-GMP or USFDA-approved facilities, Sofosbuvir is ideal for B2B licensing, tender supply, and distribution in regulated and semi-regulated markets. Offered with full CTD dossier, bioequivalence data, and stability studies, it supports rapid registration and commercialization in global markets. Available as a standalone API or FDF with partner molecules.